Navigation Links
Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
Date:11/7/2007

WESTMINSTER, Colo., Nov. 7 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the Company will participate in the 2007 JMP Securities Healthcare Focus Conference in Boston.

The Company's presentation will take place at 12 p.m. (Eastern) on Tuesday, November 13, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through November 27, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the Company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the fourth quarter of 2007. For additional information, please visit the Company's website at http://www.allos.com.

Safe
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , ... innovative,cancer therapy. , , ... Dr.Zhaohui Peng is the chairman,chief executive officer, and founder of ... Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China, , ...
... By Julia Cino, PhD , ... , Over the last ... and place genes into a variety of organisms that are quite different ... organisms is to produce,proteins. Since many proteins are of immense commercial value, ...
... for Culturing Mammalian, Insect, Plant, Bacteria, and Yeast Cells , ... Vyas, Product Manager , New ... 1-800-631-5417 or 1-732-287-1200; bioinfo@nbsc.com, www.nbsc.com/bi5.htm ... T-flasks, or roller bottles have,become the lab standard in most fermentation and cell,culture research ...
Cached Biology Technology:The Genesis of Gendicine: The Story Behind the First Gene Therapy 2The Genesis of Gendicine: The Story Behind the First Gene Therapy 3The Genesis of Gendicine: The Story Behind the First Gene Therapy 4The Genesis of Gendicine: The Story Behind the First Gene Therapy 5The Genesis of Gendicine: The Story Behind the First Gene Therapy 6The Genesis of Gendicine: The Story Behind the First Gene Therapy 7The Genesis of Gendicine: The Story Behind the First Gene Therapy 8The Genesis of Gendicine: The Story Behind the First Gene Therapy 9The Genesis of Gendicine: The Story Behind the First Gene Therapy 10The Genesis of Gendicine: The Story Behind the First Gene Therapy 11The Genesis of Gendicine: The Story Behind the First Gene Therapy 12The Genesis of Gendicine: The Story Behind the First Gene Therapy 13The Genesis of Gendicine: The Story Behind the First Gene Therapy 14The Genesis of Gendicine: The Story Behind the First Gene Therapy 15High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 2High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 3High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 4High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 5High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 6High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 7High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 8An Easy-to-Use Research Fermentor/Bioreactor 2An Easy-to-Use Research Fermentor/Bioreactor 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... UC San Diego have succeeded in visualizing the ... for growth and resistance to drought. The achievement ... determine how the hormone helps plants respond to ... continuing increase in the atmosphere,s carbon dioxide, or ... in the April 15 issue of the scientific ...
(Date:4/15/2014)... Zealand,s pastoral landscapes are some of the loveliest in ... Many of the country,s pasture soils have become enriched ... which is then eaten by the cattle and sheep ... New Zealand; cadmium-enriched soils being reported worldwide. , The ... levels in meat and dairy products, human health and ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... step in making artificial life forms from scratch. Using ... membranes, the structural envelopes that contain and support the ... of chemistry at the University of California, San Diego, ... report their success in the Journal of the ...
... leading causes of death. And yet, despite decades ... for most cancers. In addition, disappointing results from ... need for alternative methods. Mathematical modeling ... tumors in terms of differential equations and stochastic ...
... the College of Agricultural Sciences, The Pennsylvania State University, State ... Abstract Submissions: 1 March 2012 -- The Society for ... abstract for presentation at the 45th SSR Annual Meeting to ... Links to the following are to be found on the ...
Cached Biology News:Chemists synthesize artificial cell membrane 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3
... Fixed clamp trays and universal ... Magnetic drive Shaking ... 25 mm amplitude ... to 2000 ml, including Fernbach flasks ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... The CHEF-DR III variable angle system, 220-240 ... greater than 6 Mb DNA fragments by pulsed ... electrophoresis cell, power module, variable-speed pump, 14 x ... comb holder, 15-well, 1.5 mm thick comb, screened ...
Biology Products: